FindTrial
Sign In

A Phase 2 Study Evaluating the Safety and Efficacy of Neoadjuvant Amivantamab in Combination with Lazertinib or Chemotherapy in Resectable EGFR-Mutated Non-Small Cell Lung Cancer

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-524816-13-00
Enrollment
6
Registered
2026-07-27
Start date
Unknown
Completion date
Unknown
Last updated
2026-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small Cell Lung Cancer

Brief summary

MPR (≤10% residual cancer cells in the surgical specimen, per independent centralized pathology review)

Interventions

DRUGJNJ-73841937
DRUGJNJ-61186372

Sponsors

Janssen Cilag International
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
MPR (≤10% residual cancer cells in the surgical specimen, per independent centralized pathology review)—

Outcome results

None listed

Source: EU CTIS · Data processed: Jul 28, 2026